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ESSENTIALS:
 The ideal duration of treatment  for cancer-associated venous thromboembolism 
(VTE) is unknown
 Patients were randomised to rivaroxaban or placebo after approximately 6 months of 
anticoagulants
 There was a trend towards a reduction in VTE recurrence with rivaroxaban compared 
to placebo.
 The absence of residual deep vein thrombosis defined a low VTE recurrence risk 
group.
ABSTRACT
Background: The SELECT-D trial demonstrated reduction in recurrent venous 
thromboembolism (VTE) but increased bleeding with rivaroxaban compared to dalteparin for 
treatment of acute VTE in cancer patients, at 6 months. Uncertainty remains around optimal 
duration of anticoagulation.
Objectives: To assess VTE recurrence and bleeding, with anticoagulation or not, beyond 6 
months 
Patients/Methods: In SELECT-D, after 6 months of trial treatment for VTE, patients with 
active cancer and residual deep vein thrombosis (RDVT) or index pulmonary embolism (PE) 
were eligible for randomisation to a further 6 months of rivaroxaban or placebo. Patients with 
no RDVT stopped anticoagulation. Primary outcome was VTE recurrence at 12 months. The 
second randomisation closed prematurely due to low recruitment when 92 of the planned 
300 patients were recruited.
Results: 92 of 136 eligible patients were randomised to rivaroxaban or placebo. The 
cumulative VTE recurrence after 6 months from the second randomisation, was 14% with 
placebo and 4% with rivaroxaban (Hazard Ratio 0.32; 95% CI 0.06-1.58). The major and 
clinically-relevant non-major bleeding rates were 0% and 0% with placebo; and 5% (95% CI 
1-18%) and 4% (95% CI 1-17%) with rivaroxaban. In an exploratory analysis, 7 (15.2 %) of 
46 placebo patients with RDVT or an index PE experienced recurrent VTE compared to 
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Conclusion: The SELECT-D trial was underpowered to detect a statistically significant 
reduction in recurrent VTE with extended anticoagulation. The absence of RDVT and/or 
index PE, defined a population at low risk of recurrence. 
KEYWORDS:  Cancer-associated thrombosis; treatment duration; direct oral anticoagulant; 
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INTRODUCTION
Venous thromboembolism (VTE) in cancer patients is a common occurrence and can be 
clinically challenging. In many countries, low molecular weight heparin (LMWH) has been 
the standard of care for the treatment and prevention of recurrent VTE in cancer for over 15 
years (1, 2). Direct oral anticoagulants (DOACs) are emerging as an alternative treatment to 
LMWH for cancer patients with VTE based on the results of two recent randomised 
controlled trials (RCTs): the Hokusai VTE Cancer trial (3) and the SELECT-D trial (4). In the 
Hokusai VTE Cancer trial, initial dalteparin for at least 5 days followed by edoxaban was 
compared with dalteparin alone, both treatments intended for 6 to 12 months (3). The 
primary outcome was a composite of VTE recurrence and major bleeding at 12 months post-
randomisation. Edoxaban was found to be non-inferior to dalteparin. At 12 months, the 
recurrent VTE rate was higher in the dalteparin arm than in the edoxaban arm and the rate 
of major bleeding was significantly lower with dalteparin compared to edoxaban. The excess 
of major bleeding with edoxaban was confined to patients with gastrointestinal cancer. (5). In 
the SELECT-D trial, patients received rivaroxaban or dalteparin for 6 months (4). Using 
rivaroxaban reduced the 6-month VTE recurrence rate compared to dalteparin (hazard ratio 
(HR) = 0.43; 95% confidence interval (CI) 0.19-0.99). The rate of major bleeding was similar 
between groups (HR=1.83; 95%CI 0.68-4.96), but more clinically relevant non-major 
bleeding (CRNMB) was experienced by patients receiving rivaroxaban compared to 
dalteparin (HR=3.76; 95% CI 1.63-8.69). A recent meta-analysis of the efficacy and safety of 
DOACs, vitamin K antagonists (VKAs) and LMWH in patients with cancer associated 
thrombosis (CAT) found only these two aforementioned studies comparing DOAC and 
LMWH (6).
The duration of anticoagulant treatment in cancer patients with acute VTE is an unanswered 
question. Clinical practice guidelines have recommended continuing treatment for patients 
with risk factors for VTE recurrence or progression, including the presence of metastases or 
ongoing chemotherapies (7). Duration of treatment was hitherto based on the duration of 
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unprovoked VTE and not on published data; the duration differed depending on the 
anticoagulants used and the clinical circumstances. 
There are also some data to suggest that the absence of residual deep vein thrombosis 
(RDVT) on compression ultrasound (CUS) predicts a low risk group for recurrent VTE (8). 
Based on these considerations, the SELECT-D trial included a second randomisation 
designed to investigate this important question of the clinical course of VTE, with 
anticoagulation or not, beyond 6 months.  Patients in SELECT-D who had the presence of 
RDVT at approximately 5.5 months after randomisation or whose index VTE was a 
pulmonary embolism (PE) i.e. patients deemed at higher risk of VTE, were randomly 
allocated to continue rivaroxaban or placebo. The absence of RDVT mandated discontinuing 
anticoagulant therapy at 6 months. Rivaroxaban was the anticoagulant of choice as we were 
able to guage the safety of rivaroxaban in the cancer population in the first six months post-
randomisation. The focus of this manuscript is the clinical course of patients who entered the 
second randomisation. 
METHODS
Study design and patient population
The SELECT-D trial design and the population including inclusion and exclusion criteria, 
have been previously defined (4). Briefly, patients with active cancer presenting with a 
primary objectively confirmed symptomatic lower-extremity proximal deep vein thrombosis 
(DVT), symptomatic or incidental PE, were randomised to dalteparin or rivaroxaban. 
At around 5.5 months post randomisation, patients with an index DVT had a CUS to detect 
the absence or presence of a RDVT. If the CUS showed RDVT or if patients had presented 
with a PE, they were eligible to be randomly assigned to a further 6 months of rivaroxaban at 
20mg orally once daily or placebo (second randomisation). To be eligible, patients should 
have received trial treatment for 6 months, not had a VTE recurrence, have an ECOG 
performance status of <2; and have adequate haematologic, hepatic, and renal function. A 
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randomisation. However, having a bleed was not an exclusion criterion, leaving the decision 
to futher randomise or not to the discretion of the clinician. Patients with an absence of 
RDVT were not eligible for the second randomizaiton and were mandated to discontinue 
anticoagulant therapy at 6 months.
 
All patients entering the first randomisation were assessed at 3-monthly intervals until month 
12 and then 6-monthly until month 24. The trial was approved by the Coventry & 
Warwickshire Research Ethics Committee, the Health Research Agency and the Medicines 
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Random Assignment and Study Interventions
Patients consenting to the second randomisation were randomised centrally by telephoning 
Warwick Clinical Trials Unit and randomly assigned to rivaroxaban or placebo in a 1:1 ratio 
using a computer-based minimisation algorithm. Patients were stratified by the trial 
treatment during the first 6 months of the trial, type of VTE, risk of clotting by tumour type, 
stage of disease and platelet count, at the time of the second randomisation. 
Rivaroxaban and placebo were supplied by Bayer AG. The tablets were packaged, labelled 
and distributed by an independent company; the tablets and packaging were 
indistinguishable by patient or clinician. Each bottle of tablets had a unique drug pack 
number, allocated to a patient by the randomisation system. Emergency unblinding could be 
requested on safety grounds by the treating clinician by contacting an independent 
Emergency team. The treatment allocation was blinded to the patient, clinician and those 
evaluating outcomes. The treatment allocation was only unblinded to the trial statistician at 
the of the final analysis.
Outcomes
The predefined primary outcome for the patients entering the SELECT-D second 
randomisation was VTE recurrence at 12 months post first randomisation. Reported VTE 
events were adjudicated by a central committee unaware of treatment allocation after the 
last patient was entered. Predefined secondary outcomes for SELECT-D comprised major 
bleeding (9); CRNMB (10), overall survival and VTE recurrence at 12 months for the 
subgroup of patients with no RDVT. Bleeding events were adjudicated by an independent 
committee of experienced clinicians unaware of treatment allocation. 
Statistical Considerations
In SELECT-D, the assumption was made that a sample size of 530 patients would allow 
sufficient numbers (300 in total) to continue onto the second randomisation to provide 
estimates for a future definitive duration study. However, the second randomisation closed 
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Data and Safety Monitoring Committee who recognised the futility of continued recruitment. 
Any patient randomised after 1st September 2016 was not eligible for the second 
randomisation.  In addition, the protocol was also amended to exclude patients with 
esophogeal and gastro-esophogeal cancer because of a bleeding signal. This exclusion did 
not effect the patients entering the second randomisation.
For the patients in the second randomisation, the time to a VTE recurrence was calculated 
from the date of second randomisation to the date of first VTE recurrence event, or censored 
at the date last known to be VTE recurrence-free or at 6 months post entry to second 
randomisation, whichever came first. Overall survival was calculated from the date of second 
randomisation to the date of death from any cause, or censored at the date last known to be 
alive or at 6 months. 
Cumulative incidence curves for the time to a VTE recurrence were estimated using the 
complement of the Kaplan-Meier estimates. A competing risk analysis was performed using 
the cumulative incidence competing risk method to account for death as a competing risk 
(11). Kaplan-Meier estimates were also obtained for bleeding and overall survival. A Cox 
model was used to obtain hazard ratios (HRs) and associated 95% confidence interval (CIs). 
An exploratory comparison of patients with no RDVT and those with RDVT or PE on the 
placebo arm in terms of VTE recurrence was performed using the log rank test.
All analyses were performed on an intention-to-treat basis with the SAS statistical package 
version 9.4. SELECT-D was not powered for statistical testing between trial arms at 12 
months. 
RESULTS
Between 6th September 2013 and 22nd December 2016, 406 patients were randomised into 
the SELECT-D trial. Two-hundred fourteen patients (53%) were males, the median age was 
67 years (range 22-87 years), 234 (58%) had metastatic disease and 211 (52%) patients 
had an incidental PE (Table 1). The primary analyses of recurrent VTE and bleeding at 6 
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A total of 371 patients were randomised into the SELECT-D trial before participation in the 
second randomisation was closed; the remaining 35 patients were not considered for the 
second randomisation. Of the 371 patients, 94 (25%) died, 33 (9%) withdrew before 6 
months, 10 (3%) had a DVT on entry but were not assessed for RDVT (as they had already 
stopped anticoagulation, had recurrent VTE or were found to be ineligible), 35 (9%) were 
assessed and found to be RDVT negative, leaving 199 (54%) patients with RDVT on CUS or 
PE at presentation to be considered for the second randomisation (Figure 1). Of these, 63 
were excluded as they did not meet the inclusion criteria, resulting in 136 patients eligible for 
the second randomisation. Forty-four eligible patients declined to participate or their 
clinicians advised them not to (Figure 1); 4 (9%) had an index DVT, 29 (66%) had an 
incidental PE and 11 (35%) had a sympomatic PE. There were 2 VTE recurrences and 6 
deaths in this patient group between 6 and 12 months post first randomisation.
Only 92 patients were randomised (46 to rivaroxaban and 46 to placebo). The patients 
entering the second randomisation tended to have better ECOG performance status, 
early/locally advanced disease, incidental PE, and a lower risk of VTE tumour type 
compared to those 107 that were not randomised (Table 1). The patient and clinical 
characteristics were reasonably comparable between randomised treatment arms. (Table 2). 
Four patients were randomised despite having a bleed (1 major [haematoma] and 3 
CRNMB) on anticoagulation within the first six months of the trial. 
Fifty-eight (63%) of the 92 patients participating in the second randomisation completed 6 
months of additional trial treatment, six (7%) failed to start the trial treatment and 28 (30%) 
stopped treatment early due to various factors including death, VTE recurrence, bleeding 
and clinical decision (Figure 1). Two patients had their second randomised treatment 
unblinded in order to treat the patient safely; one patient had a pleural effusion and the 
other, a haematemesis associated with grade 4 thrombocytopenia.
There were six patients on the placebo arm and two patients on the rivaroxaban arm that 
had VTE recurrence within 6 months from second randomisation. Two of the placebo events 
were incidental PEs . The Kaplan-Meier estimates of VTE recurrence were 14% (95% CI 7-
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rivaroxaban arm at 6 months from second randomisation (HR=0.32; 95% CI 0.06-1.58, 
Figure 2). The incidence of VTE recurrence per subject month at risk for months 1-6 from 
the second randomisation was 3.0% (6/237) for the placebo arm patients and 0.8% (2/246) 
for those on rivaroxaban. There was no significant interaction between the first and second 
treatment arms (p=0.99) in terms of VTE recurrence i.e. the initial anticoagulation allocation 
did not impact on the VTE recurrence outcomes for patients in the second randomisation. 
Two patients, one with lung cancer; one with colorectal cancer, on the rivaroxaban arm 
experienced major bleeds (both upper gastrointestinal haemorrhages) at 1 month and 6 
months from the second randomisation, respectively; resulting in a major bleeding rate of 
5% (95% CI 1-18%). Neither resulted in death. The major bleeding rate was 0% on the 
placebo arm. An additional two patients on the rivaroxaban arm had CRNMBs at 1 and 3 
months from second randomisation for a 4% (95% CI 1-17%) CRNMB rate, due to bruising 
of the eye (gastric primary) and bleeding from the nipple (breast primary) respectively. The 
CRNMB rate was 0% on the placebo arm.
Of the 92 patients participating in the second randomisation, 11 patients died of their cancer 
(five on the placebo arm; six on the rivaroxaban arm) within 6 months of second 
randomisation. The overall survival rate for those patients on the rivaroxaban arm at 6 
months from second randomisation was 89% (95% CI 75-95%) and 87% (95% CI 73-94%) 
for those on the placebo arm (HR=1.16; 95% CI 0.36-3.81).
Of the 35 patients who had no RDVT on CUS around 5.5 months from the first 
randomisation and for whom the protocol specified stopping anticoagulation at 6 months, six 
had additional anticoagulation treatment beyond 6 months, advised by their clinicians. Three 
of the six patients had already switched from trial treatment to alternative anticoagulation 
(one at 1 month, and two at 5 months from first randomisation). For the other three patients, 
their hospital/clinician reported that they considered it appropriate to continue on 
anticoagulation as patients had active cancer and therefore still at risk due to the disease. 
None of the 35 RDVT-negative patients experienced a VTE recurrence between 6 and 12 
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cancer and one from kidney failure). In an exploratory comparison, patients with no RDVT 
were significantly less likely to have a VTE recurrence than the RDVT positive and PE 
patients receiving placebo (log rank p=0.03). 
DISCUSSION 
There is limited evidence on the duration of anticoagulation specifically in cancer patients 
with VTE. Clinical Practice Guidelines have recommended 6 months of anticoagulant 
therapy (7). Beyond the initial six months, guidelines recommend that anticoagulation should 
be considered in patients with active cancer, such as those on chemotherapy treatment (7, 
12). The clinical course of patients in SELECT-D who received anticoagulation or not 
between 6 and 12 months has provided us with the opportunity for potential insights on the 
duration of anticoagulation in cancer patients.
For those patients who participated in the second randomisation, there was a higher VTE 
recurrence rate in the placebo arm in comparison to the rivaroxaban arm, but the difference 
was not statistically significant. The failure to detect a significant difference between 6 and 
12 months of anticoagulation is likely to be the result of a lack of power from the small 
sample size. Extended treatment comes with a potential cost of bleeding. Major bleeding 
and CRNMBs on rivaroxaban in patients randomised at 6 months was 5% and 4% 
respectively. There were no major or CRNMBs for patients on placebo between 6 and 12 
months.
In the venous thrombosis literature, there is a school of thought that the duration of 
anticoagulant therapy can be tailored to the underlying risk of thrombosis i.e. provoked or 
unprovoked (13). In planning SELECT-D, we hypothesized that cancer patients with VTE 
who had received approximately 6 months of anticoagulant treatment could be stratified into 
low and high risk groups for recurrent VTE based on underlying risk for thrombosis. RDVT 
was chosen as the risk stratification approach at the time of the trial design as the results of 
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period of treatment with a LMWH is sufficient. In those with persistent RVT, treatment 
extended to 2 years substantially reduced, but did not eliminate, the risk of recurrent 
thrombosis (14). We also postulated that having had an index PE also predicted for 
recurrence. In the group of patients whom we postulated would be at low risk of recurrent 
VTE i.e. RDVT-negative (8), there were no subsequent events after 6 months. In contrast, 
there was a significant increase in recurrent VTE in the placebo patients who were deemed 
at higher risk of VTE defined by RDVT positivity or having an index PE. This exploratory 
analysis supports the hypothesis that the RDVT negative patients are a low risk group for 
VTE recurrence. However a much larger cohort would be required to provide robust 
evidence that risk stratification can help tailor duration of anticoagulant therapy. 
For patients participating in the first and second randomisations, there was a similar major 
bleeding rate on rivaroxaban between the first and second 6 months. The more than 3-fold 
reduction in CRNMBs between the second 6 months and first 6 months for the respective 
periods, suggests that patients entering the second 6-month period were fitter and at lower 
bleeding risk.
Forty-four percent of the initial 406 patients stayed on trial for 12 months; the attrition rate 
was higher in the first 6 months of the study. The survival rates were considerably higher for 
those entering the second randomisation, confirming those patients had a more favourable 
prognosis. In addition, 50% of all enrolled patients had an incidental PE, whereas this 
increased  to 66% of patients in the second randomisation, which may also reflect a more 
favourable attitude (physician and/or patient) towards randomizing a patient who has not 
associated their symptoms to a PE. 
Although the acceptance rate for those patients approached for the second randomisation 
was reasonably high at 68%, the number of eligible patients was lower than predicted. 
Twenty-five percent of patients had died and 9% had withdrawn from the trial before the 6-
month time point. Clinicians alongside the patients were choosing whether to enter the 
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anticoagulation duration study in cancer patients which failed to recruit (15). However, the 
type of VTE at trial entry and the clinical outcomes for the 44 eligible patients who did not 
participate in the second randomisation were similar to the 92 who did participate. 
Hokusai VTE Cancer (n=1050) and SELECT-D (n=406) have recently driven the use of 
DOACs for selected cancer patients with VTE. The 12-month trial outcomes for both studies 
are not directly comparable; nevertheless, the 12-month VTE recurrence for patients on a 
DOAC are similar; recurrent VTE occurred in 7.9% in the edoxaban group in the Hokusai 
VTE Cancer trial and 10% of those randomised initially to rivaroxaban in SELECT-D. 
Similarly, major bleeding at 12 months, occurred in 6.9% of the edoxaban group and 5% in 
the rivaroxaban group. The heterogeneous nature of the anticoagulation over time should be 
noted; 46 patients in SELECT-D were randomised to 6 months of placebo and 16 patients 
chose not to continue with anticoagulation, thus having no active treatment, which may 
explain the slightly higher VTE recurrence rate and lower bleeding rate with SELECT-D in 
comparison to the rates in the Hokusai VTE Cancer trial.
SELECT-D is not without limitations. It was small in size, the patient population was 
heterogeneous and potentially biased toward being the fitter patients that successfully 
completed the intitial 6 month course of anticoagulation, and clinicans did not always follow 
the study protocol. Furthermore, as SELECT-D was open to all cancer types and only stage 
of disease could be accounted for in the stratification due to the sample size, there was an 
imbalance between treatment arms for some cancer types in particular colorectal cancer and 
ovarian cancer, which could have confounded the results.
 
It is unclear whether  there will ever be a large randomised trial that specifically addresses 
the duration of anticoagulant therapy in cancer patients. Meanwhile, correlative biomarker 
research may improve risk stratification (16). In concusion, individualised, informed decision-
making between patient and clinician based on the trade-off of the risk of continuing 
thrombosis, and bleeding is recommended. SELECT-D provides  numerical values of the 
risk of recurrent VTE as well as risk of major bleeding and CRNMB when anticoagulation is 
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Table 1: Baseline patient characteristics for a) all 406 SELECT-D trial patients; b) those 92 patients that entered the second 
randomisation; c) those 107 with residual deep vein thrombosis (RDVT) positive or a pulmonary embolism (PE) at presentation 
that did not go onto the second randomisation ; and d) the 35 RDVT negative patients.






n % n % n % n %
Number of patients 406 92 107 35
Sex
Male 214 53 47 51 56 52 18 51
Female 192 47 45 49 51 48 17 49










0 120 30 36 39 31 29 13 37
1 185 46 40 44 53 49 16 46
2 95 23 14 15 22 21 5 14
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White 389 95 88 96 104 97 33 94
Mixed 3 1 1 1 1 1 1 3
Asian or British Asian 3 1 2 2 1 1 0 0
Black or Black British 6 1 1 1 1 1 0 0
Chinese or other ethnic group 3 1 0 0 0 0 0 0
Unknown 2 1 0 0 0 0 1 3
STRATIFICATION VARIABLES
Stage of disease at randomisation
Early/locally advanced disease 164 40 44 48 46 43 25 71
Metastatic disease 232 57 44 48 57 53 10 29
Haematological malignancy 10 3 4 4 4 4 0 0
Platelet count at randomisation
<=350,000/µl 336 83 84 91 89 83 32 91
>350,000/µl 70 17 8 9 18 17 3 9
Type of VTE
Symptomatic VTE 195 48 32 35 40 38 35 100
PE 80 20 22 24 26 26 0 0
DVT 110 27 10 11 14 12 35 100
PE and DVT 4 1 0 0 0 0 0 0










This article is protected by copyright. All rights reserved
Incidental PE 211 52 60 65 67 62 0 0
Risk of clotting by tumour type
High risk 339 84 72 78 90 84 28 80
Low risk 67 16 20 22 17 16 7 20
First randomised trial treatment
Dalteparin 203 50 42 46 55 51 17 49
Rivaroxaban 203 50 50 54 52 49 18 51
Tumour type
Bladder 14 3 3 3 5 5 1 3
Breast 41 10 16 16 10 9 5 14
Brain 3 1 0 0 0 0 1 3




2 2 0 0 0
0
Chronic Lymphoid Leukaemia 4 1 2 2 1 1 1 3
Colorectal 102 25 20 22 33 31 14 40
Gallbladder 4 1 0 0 0 0 0 0
Gastric 12 3 3 3 4 4 0 0
Gynaecological 13 3 2 2 5 5 0 0
Kidney 7 2 3 3 2 2 1 3
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Lymphoma 22 5 10 11 5 5 1 3
Multiple myeloma 5 1 2 2 2 2 0 0
Oesophageal/gastro-
oesophageal
29 7 7 8 4 4 3 8
Ovarian 30 7 6 7 10 9 2 6
Pancreatic 30 7 2 2 6 5 0 0
Prostate 21 5 5 6 7 6 0 0
Sarcoma 2 1 0 0 0 0 0 0
Other 12 3 1 1 2 2 3 8
Unknown 2 1 0 0 0 0 1 3
Characteristics at 5.5. months
ECOG performance status at 5.5 months
0 100 25 43 47 27 25 15 43
1 96 24 36 39 34 32 14 40
2 24 6 7 8 13 12 2 6
3 14 3 1 1 7 7 3 8
4 1 <1 0 0 1 1 0 0
Unknown 171 42 5 5 25 23 1 3
Stage of disease at 5.5. months
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Metastatic disease 238 59 44 48 59 55 11 31
Haematological malignancy 10 2 4 4 4 4 0 0
Current status of cancer
Complete Remission 35 9 15 16 13 12 4 11
Partial response 34 8 18 20 9 9 4 11
Stable disease 61 15 21 23 23 21 7 20
Progressive disease 48 12 10 11 23 21 8 23
Non-evaluable 6 1 3 3 2 2 1 3
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Table 2: Patient characteristics by the second randomisation trial allocation
Characteristic Placebo Rivaroxaban Total
n % n % n %
Number randomised 46 50 46 50 92
Sex
Male 18 39 29 63 47 51
Female 28 61 17 37 45 49
Age years (Median(Range)) 68 (30-87) 68(32-87) 68 (30-87)




ECOG performance status 
0 20 44 16 35 36 39
1 17 37 23 50 40 44
2 7 15 7 15 14 15
Unknown 2 4 0 0 2 2
Ethnicity 
White 43 94 45 98 88 96
Mixed 0 0 1 2 1 1
Asian or British Asian 2 4 0 0 2 2
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STRATIFICATION VARIABLES




24 52 20 43 44 48
Metastatic disease 21 46 23 50 44 48
Haematological malignancy 1 2 3 7 4 4
Platelet count at second 
randomisation
<=350,000/µl 42 91 42 91 84 91
>350,000/µl 4 9 4 9 8 9
Type of VTE
Symptomatic VTE 16 35 16 35 32 35
PE 10 22 12 26 22 24
DVT 6 13 4 9 10 11
Incidental PE 30 65 30 65 60 65
Risk of clotting by tumour type
High risk 36 78 36 78 72 78
Low risk 10 22 10 22 20 22
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treatment
Dalteparin 21 46 21 46 42 46
Rivaroxaban 25 54 25 54 50 54
Tumour type
Bladder 1 2 2 4 3 3
Breast 9 18 7 15 16 16
Cancer Unknown Primary 1 2 1 2 2 2
Chronic Lymphoid 
Leukaemia
0 0 2 4 2 2
Colorectal 6 13 14 31 20 22
Gastric 2 4 1 2 3 3
Gynaecological 2 4 0 0 2 2
Kidney 2 4 1 2 3 3
Lung 3 7 5 11 8 9
Lymphoma 4 9 6 13 10 11
Multiple myeloma 1 2 1 2 2 2
Oesophageal/gastro-
oesophageal
4 9 3 7 7 8
Ovarian 6 13 0 0 6 7
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Prostate 2 4 3 7 5 6
Cholangiocarcinoma 1 2 0 0 1 1
Ottawa score*
Low risk (<0) 10 22 16 35 26 28
Moderate risk (=0) 25 54 22 48 47 51
High risk (>1) 11 24 8 17 19 21
*Louzada et al. Circulation 2012 (17)
FIGURE LEGENDS
Figure 1: Consort diagram for the second randomisation
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Figure 1: Consort diagram for the second randomisation
Randomised before 1st September 2016: (n=371)
Excluded (n=107 (29%))
 Not meeting inclusion criteria (n=63)
 Declined to participate (n=44)
o Patient decision (n=21)
o Clinical decision (n=22)





 VTE recurrence (n=6); 
 Participant decision (n=1); 
 Other adverse event (n=4)
 Clinical decision (n=3)
 Non-compliant with treatment (n=1)
Allocated to Placebo (n=46)
 Received allocated intervention (n= 44)
 Did not receive allocated intervention
o Patient died (n=1)
o Patient withdrew consent for trial (n=1)
Discontinued intervention (n=12)
 Death (n=4)
 VTE recurrence (n=1); 
 Bleed (n=2)
 Other adverse event (n=2)
 Withdrawn consent (n=1)
 Clinical decision (n=1)
 Unknown (n=1)
Allocated to Rivaroxaban (n= 46)
• Received allocated intervention (n= 42)
• Did not receive allocated intervention 
o Patient died (n=1)
o Patient had a bleed prior to starting trial 
treatment (n=1)
o Patient failed to collect medication (n=1)
o Unknown reason (n-=1)
Withdrawal (n=1)





 10 (11%) DVT
 60 (65%) Incidental PE







RDVT negative (n=35 (9%)) Not assessed for 2
nd randomisation (n=137 (38%); 
127 died/withdrawn, 10 RDVT not assessed)
 43 (31%) DVT
 68 (50%) Incidental PE
 25 (18%) symptomatic PE
 1 (1%) unknown PE/DVT
RDVT positive or PE (n=199 (54%))
 24 (12%) DVT
 127 (64%) Incidental PE










This article is protected by copyright. All rights reserved


























Time since second randomisation (Months)
          Placebo
          Rivaroxaban
Numbers at Risk:
Placebo 46 40 36 35
Rivaroxaban      46 42 38 37
